11741 Results

People

  1. Vickers
    Vickers
  2. Offit
    Offit
  3. Robson
    Robson
  4. Horwitz
    Horwitz
  5. Kingham
    Kingham
  6. Panageas
    Panageas
  7. Breitbart
    Breitbart
  8. Halpern
    Halpern
  9. Jarnagin
    Jarnagin
  10. Nelson
    Nelson

Groups

  1. Population Sciences Research Program (11741)
  2. Survivorship Research (5670)
  3. Department of Medicine (5135)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3334)
  6. Surgery (2966)
  7. Psychiatry and Behavioral Sciences, Department of (2780)
  8. Biostatistics Service (2339)
  9. GSK Faculty (2009)
  10. Health Outcomes Research Group (1948)
  1. "Population Sciences Research Program"
Formats
  1. Journal Article (7144)
  2. Meeting Abstract (3307)
  3. Book Section (330)
  4. Review (289)
  5. Editorial (253)
  6. Research Letter (116)
  7. Correspondence (111)
  8. Conference Paper (67)
  9. Guidelines (59)
  10. Miscellaneous (41)
  11. Book Whole (24)
Groups
  1. Population Sciences Research Program (11741)
  2. Survivorship Research (5670)
  3. Department of Medicine (5135)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3334)
  6. Surgery (2966)

More Groups

People
  1. Andrew Vickers (880)
  2. Kenneth Offit (788)
  3. Mark Robson (676)
  4. Steven Horwitz (645)
  5. T Peter Kingham (609)
  6. Katherine Panageas (512)

More People

Years
  1. 2025 (236)
  2. 2024 (722)
  3. 2023 (821)
  4. 2022 (828)
  5. 2021 (786)
  6. 2020 (738)

More Years

Publications
  1. Journal of Clinical Oncology (1246)
  2. Blood (374)
  3. Psycho-Oncology (347)
  4. Cancer (240)
  5. Cancer Research (234)
  6. Annals of Surgical Oncology (233)

More Publications

Publishers
  1. American Society of Clinical Oncology (1412)
  2. Elsevier Inc. (1128)
  3. Springer (1112)
  4. Elsevier Science, Inc. (816)
  5. Oxford University Press (753)
  6. Wiley Blackwell (614)

More Publishers

Results (11741)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290)
    Meeting Abstract

    Schmid, P.; Cortes, J.; Robson, M. E.; Iwata, H.; Hegg, R.; Nechaeva, M.; Xu, B.; Verma, S.; Haddad, V.; Imedio, E. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Opioid safety among high-risk cancer survivors
    Meeting Abstract

    Salz, T.; Mishra, A. A.; Gennarelli, R. L.; Lipitz-Snyderman, A.; Boudreau, D.; Moryl, N.; Tringale, K. R.; Korenstein, D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
    Meeting Abstract

    Rugo, H. S.; Llombart-Cussac, A.; Andre, F.; Robson, M. E.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Ahn, J. S.; Nanda, R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Chronic opioid therapy among a high-risk cancer survivor population
    Meeting Abstract

    Salz, T.; Lavery, J. A.; Lipitz-Snyderman, A.; Boudreau, D.; Moryl, N.; Gillespie, E. F.; Korenstein, D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials
    Meeting Abstract

    McQuade, J. L.; Hammers, H. J.; Furberg, H.; Engert, A.; Andre, T.; Blumenschein, G.; Tannir, N. M.; Baron, A. D.; Larkin, J.; El-Khoueiry, A. B.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Kotecha, R.; Lee, C. H.; Knezevic, A.; Shah, N. J.; Carlo, M. I.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Do differences in the microbiome explain early onset in colon cancer?
    Meeting Abstract

    Keshinro, A.; Vanderbilt, C.; Stadler, Z. K.; Shia, J.; Gonen, M.; Chen, C. T.; Cercek, A.; Mendelsohn, R. B.; Yaeger, R.; Zehir, A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Objective and subjective vulvovaginal symptoms in breast cancer patients
    Meeting Abstract

    Goldfarb, S. B.; Saban, S.; Arkema, A.; Patil, S.; Flynn, J.; Goldfrank, D. J.; Norton, L.; Carter, J.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Impact of breast cancer chemotherapy on ovarian damage and recovery
    Meeting Abstract

    Goldfarb, S. B.; Bedoschi, G.; Turan, V.; Crown, A.; Abdo, N.; Dickler, M. N.; Oktay, K.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save